Item 7.01. Regulation FD Disclosure.

As previously announced, PTC Therapeutics, Inc. (the "Company") hosted a conference call on June 21, 2022 at 8:00 a.m. eastern time. During this conference call, the Company discussed the top-line results from the placebo-controlled trial of Study 041 for Translarna. A copy of the slide deck that was presented during the conference call is attached as Exhibit 99.1.

The information in this Current Report on Form 8-K ("Report") (including Item 7.01 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.                                Description
    99.1          Corporate Presentation - Study 041 Update
                The cover page from this Current Report on Form 8-K, formatted in
    104         Inline XBRL

© Edgar Online, source Glimpses